Overview

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

Pharmacia and Upjohn
Triangle Pharmaceuticals

Treatments:

Delavirdine
Didanosine
Emivirine
HIV Protease Inhibitors
Hydroxyurea
Protease Inhibitors
Stavudine